These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35278817)

  • 1. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
    Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
    Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acute respiratory syndrome coronavirus 2 infection in patients with autoimmune bullous diseases in China.
    Zhang JL; Wang SH; Cui SN; Zhang J; Li SZ; Li L; Zuo YG
    J Dermatol; 2023 Nov; 50(11):1433-1441. PubMed ID: 37501390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.
    Rasner CJ; Schultz B; Bohjanen K; Pearson DR
    J Med Case Rep; 2023 Sep; 17(1):408. PubMed ID: 37749657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
    Hinterseher J; Hertl M; Didona D
    J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
    Akoglu G
    Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of autoimmune bullous diseases in Middle Franconia.
    Sollfrank L; Schönfelder V; Sticherling M
    Front Immunol; 2023; 14():1256617. PubMed ID: 37881435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review.
    Russo D; Accarino R; Varricchio S; Franca RA; Potestio L; Patruno C; Napolitano M; Mascolo M
    Pathol Res Pract; 2023 Feb; 242():154300. PubMed ID: 36638589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemphigus vulgaris after the second dose of COVID-19 vaccination: a case report.
    Khalayli N; Omar A; Kudsi M
    J Med Case Rep; 2023 Jul; 17(1):322. PubMed ID: 37496035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.
    Wu PC; Huang IH; Wang CY; Chi CC
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
    Sami N; Ahmed AR
    Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic oral diseases secondary to COVID-19 infection or vaccination: clinical cases and a narrative review.
    Fitzpatrick S; Cha S; Katz J; Migliorati C
    Quintessence Int; 2024 May; 55(5):400-411. PubMed ID: 38415994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
    Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
    Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review.
    Caironi V; Pitoia F; Trimboli P
    Front Endocrinol (Lausanne); 2022; 13():900964. PubMed ID: 35813627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.